Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

Published:2022-09 Issue:9 Volume:23 Page:1145-1155
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dummer Reinhard,Queirolo Paola,Abajo Guijarro Ana Maria,Hu Youyou,Wang Dao,de Azevedo Sergio Jobim,Robert Caroline,Ascierto Paolo Antonio,Chiarion-Sileni Vanna,Pronzato Paolo,Spagnolo Francesco,Mujika Eizmendi Karmele,Liszkay Gabriella,de la Cruz Merino Luis,Tawbi Hussein

Funder

F. Hoffmann-La Roche

Roche

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial;Long;Lancet Oncol,2012

2. Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study;Dummer;Eur J Cancer,2014

3. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial;Davies;Lancet Oncol,2017

4. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study;McArthur;Ann Oncol,2017

5. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma;Geukes Foppen;Melanoma Res,2018

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers;International Journal of Molecular Sciences;2024-01-03

2. DHX38 enhances proliferation, metastasis, and EMT progression in NSCLC through the G3BP1-mediated MAPK pathway;Cellular Signalling;2024-01

3. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations;Nature Reviews Immunology;2023-12-06

4. Quoi de neuf en oncodermatologie ?;Annales de Dermatologie et de Vénéréologie - FMC;2023-12

5. Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS;Melanoma Research;2023-11-13